MAY 06, 2019 7:17 AM PDT

New insights on childhood cancer

Malignant rhabdoid tumor (MRT) is one of the worst cancer diagnoses a child can receive. While it is uncommon (or perhaps because it is), there are no standard effective treatments for MRT and most children will survive under a year.

MRT is so aggressive because it involves the loss of an anti-cancer protein called SNF5. The inactivation of SNF5 means that tumors are not suppressed; at the same time, the lost SNF5 also enables a pro-cancer protein called MYC to accelerate cancerous growth. Understanding this relationship has guided new research from Vanderbilt University, as scientists believe that targeting MYC in MRT patients might provide an effective treatment option.

"One of the difficulties in treating a cancer like MRT is that it's driven by the loss of a particular protein from the tumor cell," said William Tansey, PhD, Ingram Professor of Cancer Research and Professor of Cell and Developmental Biology. "Showing that MYC is activated by SNF5 loss identifies a target you can conceivably go after in these cancers," he said.

MRT cancer is one of the most aggressive pediatric cancers. Photo: Pixabay

MYC refers to a group of three related proteins that work as transcriptional regulators, meaning they control the expression of many genes linked to cell growth, proliferation, metabolism and genomic instability. In people with cancer, these proteins are expressed too much, which result in malignant tumors and cancerous growth. MYC overexpression leads to 100,000 cancer deaths annually in the United States.

Tansey and his colleagues are hoping that this new understanding of the connection between SNF5 and MYC proteins will promote future research in the field. As reported by Science Daily, the team of researchers utilized biochemical and genomic approaches to show that “SNF5 selectively inhibited binding of MYC to DNA, something that is required for its tumorigenic function. Accordingly, the reintroduction of SNF5 into MRT cells also displaced MYC from chromatin (the complex of DNA, RNA and protein that form chromosomes), inhibiting pro-cancerous gene expression programs.”

The research was published recently in the journal Nature Communications.

Sources: Nature Communications, Science Daily

About the Author
  • Kathryn is a curious world-traveller interested in the intersection between nature, culture, history, and people. She has worked for environmental education non-profits and is a Spanish/English interpreter.
You May Also Like
APR 23, 2020
Cancer
APR 23, 2020
Doctors, watch out for unexpected side effects in small clinical trials
Doctors who have patients in small-sized clinical trials that test new cancer drugs should be on the look-out for unexpe ...
APR 25, 2020
Cancer
APR 25, 2020
Breaking the Blood-Brain Barrier in the Fight Against Brain Cancer
One of the more unique aspects of the human body is the blood-brain barrier (BBB) that protects the central nervous syst ...
APR 17, 2020
Drug Discovery & Development
APR 17, 2020
Overcoming Multi-Drug Resistance in Cancer
Resistance to chemotherapeutic use in caner patients is something that is inevitable. Continued resistance to these drug ...
APR 27, 2020
Cancer
APR 27, 2020
Talazoparib offers improved quality of life for breast cancer patients
Findings from the Phase III EMBRACA trial have been reported at the American Association for Cancer Research (AACR) annu ...
MAY 07, 2020
Cell & Molecular Biology
MAY 07, 2020
How the Function of a Critical Immune Cell is Related to Metabolism
This work suggests that it may be possible to dampen autoimmunity or promote an immune attack on cancer through a bioche ...
MAY 13, 2020
Cancer
MAY 13, 2020
What role does geography play in childhood cancer?
Research published in the International Journal of Health Geographics aims to explain the role that geography plays in p ...
Loading Comments...